Patents Assigned to ZIELBIO, INC.
  • Plectin-1 binding antibodies and uses thereof
    Patent number: 12053530
    Abstract: Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. The disclosure relates, in part, to combinations of therapeutic agents (e.g., anti-plectin-1 antibodies and certain small molecules) that function together (e.g., synergistically) to inhibit cancer cell growth. In some embodiments, the disclosure relates to anti-plectin-1 antibody-drug-conjugates (ADCs).
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: August 6, 2024
    Assignee: ZielBio, Inc.
    Inventor: Kimberly A. Kelly
  • Plectin-1 binding antibodies and uses thereof
    Patent number: 11168145
    Abstract: Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. In some embodiments, the disclosure provides anti-plectin-1 antibodies. In some embodiments, the anti-plectin-1 antibodies are conjugated to a targeted moiety (e.g., a therapeutic moiety or a detectable label).
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 9, 2021
    Assignee: ZIELBIO, INC.
    Inventors: Kimberly A. Kelly, Julien Dimastromatteo